TWI878430B - 新型多肽複合物 - Google Patents

新型多肽複合物 Download PDF

Info

Publication number
TWI878430B
TWI878430B TW110100845A TW110100845A TWI878430B TW I878430 B TWI878430 B TW I878430B TW 110100845 A TW110100845 A TW 110100845A TW 110100845 A TW110100845 A TW 110100845A TW I878430 B TWI878430 B TW I878430B
Authority
TW
Taiwan
Prior art keywords
chain
sequence
seq
obscurin
titin
Prior art date
Application number
TW110100845A
Other languages
English (en)
Chinese (zh)
Other versions
TW202128770A (zh
Inventor
應華
胡齊悅
張玲
毛浪勇
石金平
黎婷婷
賴煒明
覃千山
金薪盛
陶維康
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
大陸商上海恆瑞醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司, 大陸商上海恆瑞醫藥有限公司 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW202128770A publication Critical patent/TW202128770A/zh
Application granted granted Critical
Publication of TWI878430B publication Critical patent/TWI878430B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110100845A 2020-01-09 2021-01-08 新型多肽複合物 TWI878430B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010020878 2020-01-09
CN202010020878.7 2020-01-09

Publications (2)

Publication Number Publication Date
TW202128770A TW202128770A (zh) 2021-08-01
TWI878430B true TWI878430B (zh) 2025-04-01

Family

ID=76787741

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110100845A TWI878430B (zh) 2020-01-09 2021-01-08 新型多肽複合物

Country Status (9)

Country Link
US (1) US20230120270A1 (https=)
EP (1) EP4089111A4 (https=)
JP (1) JP7773981B2 (https=)
KR (1) KR20220123072A (https=)
CN (1) CN114746440B (https=)
AU (1) AU2021205561A1 (https=)
CA (1) CA3164979A1 (https=)
TW (1) TWI878430B (https=)
WO (1) WO2021139758A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3981788A4 (en) 2019-06-04 2023-03-22 Jiangsu Hengrui Medicine Co., Ltd. ANTIBODY CAPABLE OF BINDING THYMIC STROMAL LYMPHOPOIETIN AND ITS USE
MX2023006596A (es) * 2020-12-03 2023-06-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica de anticuerpo anti-tslp y uso de la misma.
TW202317635A (zh) * 2021-07-14 2023-05-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｈｇｆｒ和ｅｇｆｒ的抗原結合分子及其醫藥用途
WO2023147784A1 (zh) 2022-02-07 2023-08-10 江苏恒瑞医药股份有限公司 特异性结合psma和cd3的抗原结合分子及其医药用途
CN118660910A (zh) 2022-03-14 2024-09-17 江苏恒瑞医药股份有限公司 特异性结合gprc5d和cd3的抗原结合分子及其医药用途
TW202405015A (zh) * 2022-04-11 2024-02-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｐｓｍａ和ｃｄ２８的抗原結合分子及其醫藥用途
TW202413416A (zh) * 2022-04-11 2024-04-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｅｇｆｒ和ｃｄ２８的抗原結合分子及其醫藥用途
EP4545564A4 (en) * 2022-06-23 2026-01-14 Jiangsu Hengrui Pharmaceuticals Co Ltd Antigen-binding molecule specifically binding to DLL3 and CD3, and its pharmaceutical use
TW202413437A (zh) 2022-08-05 2024-04-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｇｕｃｙ２ｃ和ｃｄ３的抗原結合分子及其醫藥用途
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
CN121712807A (zh) 2023-08-31 2026-03-20 江苏恒瑞医药股份有限公司 Ctla4/tigit结合蛋白及其医药用途
WO2025082377A1 (zh) * 2023-10-17 2025-04-24 江苏恒瑞医药股份有限公司 一种抗tslp抗体的药物组合物及其用途
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108601830A (zh) * 2015-12-18 2018-09-28 比奥根Ma公司 双特异性抗体平台

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5889151A (en) 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2007062037A2 (en) * 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
AU2006333077A1 (en) 2005-12-15 2007-07-12 Becton, Dickinson And Company Diagnosis of sepsis
AU2008247649A1 (en) 2007-05-01 2008-11-13 University Of Miami Transcriptomic biomarkers for individual risk assessment in new onset heart failure
WO2012142159A2 (en) * 2011-04-11 2012-10-18 The Brigham And Women's Hospital, Inc Structural mutations in titin cause dilated cardiomyopathy
WO2014014796A1 (en) * 2012-07-18 2014-01-23 Eli Lilly And Company Multi-specific igg-(fab)2 constructs containing t-cell receptor constant domains
CN104619715B (zh) 2012-09-14 2018-06-05 弗·哈夫曼-拉罗切有限公司 包含至少两个不同实体的分子的生产和选择方法及其用途
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108601830A (zh) * 2015-12-18 2018-09-28 比奥根Ma公司 双特异性抗体平台

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Pernigo, S., Fukuzawa, A., Pandini, A., Holt, M., Kleinjung, J., Gautel, M., & Steiner, R. A. The crystal structure of the human titin: obscurin complex reveals a conserved yet specific muscle M-band zipper module. Journal of molecular biology 427(4) 2015 718-736.
期刊 Wu, X., Sereno, A. J., Huang, F., Zhang, K., Batt, M., Fitchett, J. R., ... & Demarest, S. J. Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies. MAbs 7(2) 2015 364-372;期刊 Pernigo, S., Fukuzawa, A., Pandini, A., Holt, M., Kleinjung, J., Gautel, M., & Steiner, R. A. The crystal structure of the human titin: obscurin complex reveals a conserved yet specific muscle M-band zipper module. Journal of molecular biology 427(4) 2015 718-736. *

Also Published As

Publication number Publication date
EP4089111A4 (en) 2023-10-04
KR20220123072A (ko) 2022-09-05
CA3164979A1 (en) 2021-07-15
JP7773981B2 (ja) 2025-11-20
JP2023509212A (ja) 2023-03-07
US20230120270A1 (en) 2023-04-20
WO2021139758A1 (zh) 2021-07-15
TW202128770A (zh) 2021-08-01
CN114746440A (zh) 2022-07-12
EP4089111A1 (en) 2022-11-16
CN114746440B (zh) 2024-11-15
AU2021205561A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
TWI878430B (zh) 新型多肽複合物
US20260022166A1 (en) Antibody capable of binding to thymic stromal lymphopoietin and use therof
CN112625136B (zh) 针对冠状病毒具有中和活性的双特异性抗体及其用途
TWI830151B (zh) 抗GPRC5DxBCMAxCD3三特異性抗體及其用途
CN107614529B (zh) Pd-l1抗体、其抗原结合片段及其医药用途
TWI781108B (zh) 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN104271602B (zh) 双特异性抗体
TW201837056A (zh) Ｂ７－ｈ３抗體、其抗原結合片段及其醫藥用途
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
KR102709785B1 (ko) Ｉｌ－５ 항체, 이의 항원 결합 단편 및 이의 의학적 적용
TW202311295A (zh) 一種抗原結合分子
WO2024017326A1 (zh) 抗gprc5d纳米抗体及其应用
EP4663661A1 (en) Anti-cdh6 antibody and use thereof
JP2025526279A (ja) 抗ＴＮＦα抗体および組成物
RU2847355C1 (ru) Новый полипептидный комплекс
HK40076302B (zh) 新型多肽复合物
HK40076302A (en) New polypeptide complex
TW202602945A (zh) 抗ｇｕｃｙ２ｃ抗體及其多特異性抗體的用途
WO2024255756A1 (zh) 基于共同轻链产生双特异性抗体的方法
CN118355032A (zh) Bcma抗体及其应用
HK40106257A (zh) 新型抗sirpa抗体
CN121752595A (zh) Igf-1r及tshr结合蛋白及其医药用途
HK40110110A (zh) 具有经修饰的ch2-ch3序列的犬抗体
CN121532424A (zh) Btn3a结合蛋白及其医药用途